Literature DB >> 1333924

The B cell repertoire in patients with systemic autoimmune diseases: analysis of Epstein-Barr virus (EBV)-inducible circulating precursors that produce autoantibodies against nuclear ribonucleoprotein (nRNP).

M Okawa-Takatsuji1, S Aotsuka, S Uwatoko, M Sumiya, R Yokohari.   

Abstract

Peripheral blood B cells from patients with systemic autoimmune disease and healthy volunteers were immortalized using EBV and the frequencies of B cell precursors that produced immunoglobulin class-specific antibodies against anti-nRNP, a specific marker for mixed connective tissue disease, were assessed using limiting dilution analysis. The frequencies of EBV-induced B cell precursors that produced IgG anti-nRNP were correlated closely with the serum titres of the corresponding autoantibodies, which indicates that B cell precursors that produced potentially pathogenic autoantibodies could be immortalized from the peripheral blood of the patients by EBV. In contrast, the frequency of EBV-induced B cell precursors that produced IgM anti-nRNP in patients with systemic autoimmune disease was comparable to that in healthy volunteers and greater than those that produced IgG and IgA anti-nRNP. Moreover, many of the clones that produced IgM antibodies against nRNP reacted with other autoantigens, such as double-stranded DNA, single-stranded DNA and rabbit IgG. These polyreactive IgM antibodies are believed to belong to the 'natural antibodies', to be coded by the germline immunoglobulin V genes, and to react with evolutionarily conserved structural cellular components, including nRNP. Our finding that nRNP is one of the target antigens for this polyreactive autoantibody may lead to the elucidation of the origin of the pathogenic IgG and IgA anti-nRNP antibodies found in sera from patients with systemic autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1333924      PMCID: PMC1554590          DOI: 10.1111/j.1365-2249.1992.tb05861.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  The antibody repertoire of early human B cells. I. High frequency of autoreactivity and polyreactivity.

Authors:  P M Lydyard; R Quartey-Papafio; B Bröker; L Mackenzie; J Jouquan; M A Blaschek; J Steele; M Petrou; P Collins; D Isenberg
Journal:  Scand J Immunol       Date:  1990-01       Impact factor: 3.487

2.  The B cell repertoire in rheumatoid arthritis. I. Frequency of EBV-inducible circulating precursors producing autoantibodies.

Authors:  M Moynier; M Abderrazik; M Rucheton; B Combe; J Sany; J Brochier
Journal:  J Autoimmun       Date:  1991-08       Impact factor: 7.094

Review 3.  Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes.

Authors:  P Casali; A L Notkins
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

4.  The use of immunoblotting and immunoprecipitation of (U) small nuclear ribonucleoproteins in the analysis of sera of patients with mixed connective tissue disease and systemic lupus erythematosus. A cross-sectional, longitudinal study.

Authors:  I Pettersson; G Wang; E I Smith; H Wigzell; E Hedfors; J Horn; G C Sharp
Journal:  Arthritis Rheum       Date:  1986-08

5.  Definition of the antigenic polypeptides in the Sm and RNP ribonucleoprotein complexes.

Authors:  P J White; S O Hoch
Journal:  Biochem Biophys Res Commun       Date:  1981-09-16       Impact factor: 3.575

6.  Probing the normal and autoimmune B cell repertoire with Epstein-Barr virus. Frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus.

Authors:  M Nakamura; S E Burastero; Y Ueki; J W Larrick; A L Notkins; P Casali
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

7.  Antibodies against sulphatide in sera from patients with autoimmune rheumatic diseases.

Authors:  S Aotsuka; M Okawa-Takatsuji; S Uwatoko; R Yokohari; Y Ikeda; G Toda
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

8.  Clinical profiles of patients with antibodies to nuclear ribonucleoprotein.

Authors:  J Calderon; V Rodriguez-Valverde; S Sanchez Andrade; J L Riestra; J Gomez-Reyno
Journal:  Clin Rheumatol       Date:  1984-12       Impact factor: 2.980

9.  The double reactivity of a human monoclonal rheumatoid factor to IgG and histones is related to distinct binding sites.

Authors:  J L Pasquali; G Azerad; T Martin; S Muller
Journal:  Eur J Immunol       Date:  1988-07       Impact factor: 5.532

10.  Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells.

Authors:  R Yarchoan; G Tosato; R M Blaese; R M Simon; D L Nelson
Journal:  J Exp Med       Date:  1983-01-01       Impact factor: 14.307

View more
  4 in total

1.  Analysis of the in vitro effect of exogenous nitric oxide on human lymphocytes.

Authors:  A S Shoker; H Yang; M A Murabit; H Jamil; A al-Ghoul; K Okasha
Journal:  Mol Cell Biochem       Date:  1997-06       Impact factor: 3.396

2.  Endothelial cell-binding activity of anti-U1-ribonucleoprotein antibodies in patients with connective tissue diseases.

Authors:  M Okawa-Takatsuji; S Aotsuka; S Uwatoko; M Takaono; K Iwasaki; M Kinoshita; M Sumiya
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

3.  Calcitonin inhibits production of immunoglobulins, rheumatoid factor and interleukin-1 by mononuclear cells from patients with rheumatoid arthritis.

Authors:  S Aida; M Okawa-Takatsuji; S Aotsuka; K Shimoji; R Yokohari
Journal:  Ann Rheum Dis       Date:  1994-04       Impact factor: 19.103

4.  Enhanced synthesis of cytokines by peripheral blood monocytes cultured in the presence of autoantibodies against U1-ribonucleoprotein and/or negatively charged molecules: implication in the pathogenesis of pulmonary hypertension in mixed connective tissue disease (MCTD).

Authors:  M Okawa-Takatsuji; S Aotsuka; S Uwatoko; M Sumiya; R Yokohari
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.